International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN. 

Efflux Pumps of Mycobacterium tuberculosis: Expression analysis and in-silico characterization

    ,

Author Affiliations

  • 1Department of Biotechnology, Nrupathunga University, Nrupathunga Road, Bangalore, Karnataka 560001, India
  • 2Clinical Microbiology Division, Indian Institute of Integrative Medicine (CSIR), Canal Road, Jammu 180 001, India

Res. J. Recent Sci., Volume 15, Issue (3), Pages 16-28, July,2 (2026)

Abstract

Multidrug resistant tuberculosis, a global threat to the world community, involves high cost and long duration of treatment. Emergence of drug resistance is attributed to activity of efflux pumps as one of the earliest cause in mycobacterium. Here we show the real time expression profiles of 20 probable efflux pumps of Mycobacterium tuberculosis under the two most important drugs of antiTB regime – rifampin and isoniazid. Under rifampin pressure 10 efflux pump genes were over expressed (Rv1258c, Rv1410c, Rv1819c, Rv1145, Rv2936, Rv2937, Rv0849, Rv1877, Rv2209, and Rv0783). Under isoniazid pressure 4 efflux pump genes were induced (Rv1258c, Rv1819c, Rv2938, and Rv3065). The three dimensional structure of Rv1410c was modelled that shares significant structural similarity with MFS transporter proteins. Docking with rifampin revealed the drug’s binding pattern. It is hoped that current study will provide significant information regarding efflux mediated drug resistance of mycobacterium and can facilitate the development of new potent efflux pump inhibitors against tuberculosis.

References

  1. World Health Organization. (2023)., Global tuberculosis report 2023., World health organization.
  2. Datta, D., Jamwal, S., Jyoti, N., Patnaik, S., & Kumar, D. (2024)., Actionable mechanisms of drug tolerance and resistance in Mycobacterium tuberculosis., The FEBS journal, 291(20), 4433-4452.
  3. Udwadia Z.F., Amale, R. A., Ajbani, K. K., & Rodrigues, C. (2012)., Totally drug-resistant tuberculosis in India., Clinical Infectious Diseases, 54(4), 579–581.
  4. Nikaido, H. (2001)., Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria., Seminar in Cell and Developmental Biology, 12, 215–223
  5. Heym, B., Alzari, P.M., Honore, N. & Cole, S.T. (1995)., Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis., Molecular Microbiology, 15, 235–245.
  6. Heym, B., Saint-Joanis, B. & Cole, S.T. (1999)., The molecular basis of isoniazid resistance in Mycobacterium tuberculosis., Tubercle and Lung Disease, 79, 267–271.
  7. Ramaswamy, S. V., Reich, R., Dou, S. J., Jasperse, L., Pan, X., Wanger, A., ... & Graviss, E. A. (2003)., Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis., Antimicrobial agents and chemotherapy, 47(4), 1241-1250.
  8. Baulard, A. R., Betts, J.C., Engohang-Ndong, J., Quan, S., McAdam, R.A., Brennan, P.J., Locht, C. and Besra, G.S. (2000)., Activation of the pro-drug ethionamide is regulated in mycobacteria., Journal of Biological Chemistry. 275, 28326–28331.
  9. Morlock, G.P., Metchock, B., Sikes, D., Crawford, J.T. and Cooksey, R.C. (2003)., Eth A, inh A, and kat Gloci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates., Antimicrobial agents and Chemotherapy 47, 3799–3805.
  10. Zainuddin, Z.F. and Dale, J.W. (1990)., Does Mycobacterium tuberculosis have plasmids?, Tubercle 71:43–49.
  11. Telenti, A. (1997)., Genetics of drug resistance in tuberculosis., Clinics in Chest Medicine, 18, 55–64.
  12. Mitchison, D. A. (1979)., Basic mechanisms of chemotherapy., Chest, 76(6), 771-776.
  13. Musser J. M. (1995)., Antimicrobial agent resistance in mycobacteria: molecular genetics insights., Clinical Microbiology Reviews, 8, 496–514.
  14. Hazbon, M.H., Brimacombe, M., Bobadilla Del Valle, M., Cavatore, M., Guerrero, M.I., Varma-Basil, M., Billman-Jacobe, H., Lavender, C., Fyfe, J., García-García, L. & León, C.I., (2006)., Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis., Antimicrobial agents and Chemotherapy, 50, 2640–2649.
  15. Basso L.A., Zheng R., Musser J.M., Jacobs Jr, W.R., & Blanchard J.S. (1998)., Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates., Journal of Infectious Diseases, 178, 769–775.
  16. Miesel L., Weisbrod T.R., Marcinkeviciene J.A., Bittman, R., & Jacobs, W.R.Jr. (1998)., NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis., Journal of Bacteriology, 180, 2459–67.
  17. Larsen, M.H., Vilchèze, C., Kremer, L., Besra, G.S., Parsons, L., Salfinger, M., Heifets, L., Hazbon, M.H., Alland, D., Sacchettini, J.C. & Jacobs, W.R. Jr. (2002)., Over expression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis., Molecular Microbiology, 46, 453–466.
  18. Dalla Costa, E.R., Ribeiro, M.O., Silva, M.S., Arnold, L.S., Rostirolla, D.C., Cafrune, P.I., Espinoza, R.C., Palaci, M., Telles, M.A., Ritacco, V., Suffys, P.N., Lopes, M.L., Campelo, C.L., Miranda, S.S., Kremer, K., da Silva, P.E., Fonseca, Lde S., Ho, J.L., Kritski, A.L. & Rossetti, M.L. (2009)., Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America., BMC Microbiology, 9, 39.
  19. Ando H., Kitao T., Miyoshi-Akiyama T., Kato, S., Mori, T., &Kirikae, T. (2011)., Downregulation of katG expression is associated with isoniazid resistance in Mycobacterium tuberculosis., Molecular Microbiology, 79: 1615–28.
  20. Louw, G.E., Warren, R.M., Gey van Pittius, N.C., McEvoy, C.R.E., Van Helden, P.D. & Victor, T.C. (2009)., A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance., Antimicrobial agents and Chemotherapy, 53(8), 3181-3189.
  21. Dhamdhere, G. & Zgurskaya, H.I. (2010)., Metabolic shutdown in Escherichia coli cells lacking the outer membrane channel TolC., Molecular Microbiology, 77, 743–754.
  22. Lau, S.Y. & Zgurskaya, H.I. (2005)., Cell division defects in Escherichia coli deficient in the multidrug efflux transporter AcrEF-TolC., Journal of Bacteriology, 187, 7815–7825.
  23. Krulwich, T.A., Lewinson. O., Padan, E., & Bibi, E. (2005)., Do physiological roles foster persistence of drug/multidrug-efflux transporters? A case study., Nature Reviews Microbiology, 3, 566 –572.
  24. De Rossi, E., Aı́nsa, J. A, & Riccardi, G. (2006)., Role of mycobacterial efflux transporters in drug resistance: an unresolved question., FEMS Microbiology Reviews, 30, 36–52.
  25. Pasipanodya, J.G. & Gumbo, T. (2011)., A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs., Current Opinion in Pharmacology, 11(5), 457–463.
  26. Adams, K. N., Takaki, K., Connolly, L. E., Wiedenhoft, H., Winglee, K., Humbert, O., Edelstein, P. H., Cosma, C. L., & Ramakrishnan, L. (2011)., Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism., Cell, 145, 39–53.
  27. Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S.V., Eiglmeier, K., Gas, S., Barry, C.E. III, Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K. & Barrell, B.G. (1998)., Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence., Nature, 393, 537–544.
  28. MA, W. (2006)., Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard., Clsi (Nccls), 26, M7-A7.
  29. Eliopoulos, G.M. & Wennersten, C.B. (2002)., Antimicrobial activity of quinupristin–dalfopristin combined with other antibiotics against vancomycin-resistant enterococci., Antimicrobial agents and Chemotherapy, 46, 1319–24.
  30. Alvireaz-Freits, E.J., Carter, J.L. & Cynamon, M.H. (2002), In vitro and in vivo activity of gatifloxacin against Mycobacterium tuberculosis., Antimicrobial agents and Chemotherapy, 46, 1022–5.
  31. Sanger, G., & Goldstein, C. (2001)., Principles, workflows and advantages of the new Light Cycler Relative Quantification Softwar., Biochemical, 3, 15-17
  32. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990)., Basic local alignment search tool., Journal of molecular biology, 215(3), 403-410.
  33. Jiang, D., Zhao, Y., Wang, X., Fan, J., Heng, J., Liu, X., Feng, W., Kang, X., Huang, B., Liu, J., & Zhang, X.C. (2013)., Structure of the YajR transporter suggests a transport mechanism based on the conserved motif A., Proceedings of the National Academy of Sciences of the United States of America, 110, 14664-14669.
  34. Sali, A., & Blundell, T.L. (1993)., Comparative protein modelling by satisfaction of spatial restraints., Journal of Molecular Biology, (3), 779–815
  35. Wiederstein M. & Sippl M.J. (2007)., ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins., Nucleic Acids Research, 35, W407–W410.
  36. Glaser, F., Pupko, T., Paz, I., Bell, R.E., Bechor, D., Martz, E. & Ben-Tal, N. (2003)., ConSurf: Identification of Functional Regions in Proteins by Surface-Mapping of Phylogenetic Information., Bioinformatics, 19, 163-164.
  37. Laurie, A.T. & Jackson, R.M. (2005)., Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites., Bioinformatics, 21, 1908-1916
  38. Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S. & Olson, A. J. (2009)., Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility., Journal of Computational Chemistry, 16, 2785-91
  39. Hete´nyi, C. & van der Spoel, D. (2002)., Efficient docking of peptides to proteins without prior knowledge of the binding site., Protein Science, 11, 1729–1737.
  40. Wallace, A.C., Laskowski, R.A. & Thornton, J.M. (1995)., LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions., Protein Engineering, Design and Selection, 8, 127–134
  41. Khan, I.A., Mirza, Z.M., Kumar, A., Verma, V., & Qazi, G.N. (2006)., Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus., Antimicrobial Agents and Chemotherapy, 50, 810-812
  42. Zhang, J.R., Li, G.L., Zhao, X.Q., Wan, K.L. &Lü, J.X. (2013)., A primary investigation on the isoniazid-induced alterations in efflux gene expression among the isoniazid resistant Mycobacteriumtuberculosis clinical isolates., Zhonghua Liu Xing Bing Xue Za Zhi, 34(4), 379-84
  43. Jiang, X., Zhang, W., Zhang, Y., Gao, F., Lu, C., Zhang, X., & Wang, H. (2008)., Assessment of efflux pump gene expression in a clinical isolate Mycobacteriumtuberculosis by real-time reverse transcription PCR., Microbial drug resistance, 14(1), 7-11.
  44. Gupta, A.K., Katoch, V.M., Chauhan, D.S., Sharma, R., Singh, M., Venkatesan, K. & Sharma, V.D. (2010)., Microarray analysis of efflux pump genes in multidrug-resistant Mycobacteriumtuberculosis during stress induced by common anti-tuberculous drugs., Microbial drug resistance, 16(1), 21-8.
  45. Machado, D., Couto, I., Perdigão, J., Rodrigues, L., Portugal, I., Baptista, P., Veigas, B., Amaral, L., & Viveiros, M. (2012)., Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis., PLOSone, 7(4), e34538
  46. Rodrigues, L., Villellas, C., Bailo, R., Viveiros, M. &Aínsa, J.A. (2013)., Role of the Mmr efflux pump in drug resistance in Mycobacterium tuberculosis., Antimicrobial Agents and Chemotherapy, 57(2), 751-7.
  47. Ghajavand, H., Kargarpour Kamakoli, M., Khanipour, S., Pourazar Dizaji, S., Masoumi, M., Rahimi Jamnani, F., ... & Vaziri, F. (2019)., Scrutinizing the drug resistance mechanism of multi-and extensively-drug resistant Mycobacterium tuberculosis: mutations versus efflux pumps., Antimicrobial Resistance & Infection Control, 8(1), 70.
  48. Gupta, A.K., Chauhan, D.S., Srivastava, K., Das, R., Batra, S., Mittal, M., Goswami, P., Singhal, N., Sharma, V.D., Venkatesan, K., Hasnain, S.E. & Katoch, V.M. (2006)., Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria., Journal of Communicable Diseases, 38(3), 246-54.
  49. Pang, Y., Lu, J., Wang, Y., Song, Y., Wang, S., & Zhao, Y. (2013)., Study of the Rifampin monoresistance mechanism in Mycobacterium tuberculosis., Antimicrobial Agents and Chemotherapy, 57, 893-900
  50. Silva, P.E., Bigi, F., Santangelo, M.P., Romano, M.I., Martín, C., Cataldi, A. & Aínsa, J.A. (2001)., Characterization of P55, a multidrug efflux pump in Mycobacteriumbovis and Mycobacterium tuberculosis., Antimicrobial Agents and Chemotherapy, 45(3), 800-4.
  51. Rodrigues, L., Machado, D., Couto, I., Amaral, L. & Viveiros, M. (2012)., Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex., Infection, Genetics and Evolution, (4), 695-700.
  52. Kaatz, G.W., Thyagarajan, R.V. & Seo, S.M. (2005)., Effect of promoter region mutations and mgrAoverexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter., Antimicrobial Agents and Chemotherapy, 49, 161–169.
  53. Piddock, L.J.V. (2006)., Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria., Clinical microbiology reviews, 19(2), 382-402.
  54. Yan, N. (2013)., Structural advances for the major facilitator superfamily (MFS) transporters., Trends in Biochemical Sciences, 38(3), 151-159
  55. Sun, L., Zeng, X., Yan, C., Sun, X., Gong, X., Rao, Y., & Yan, N. (2012)., Crystal structure of a bacterial homologue of glucose transporters GLUT1–4., Nature, 490(7420), 361-366.
  56. Pao, S.S., Paulsen, I.T. & Saier, M.H. Jr. (1998)., Major facilitator superfamily., Microbiology and Molecular Biology Reviews, 62, 1–34
  57. Marger, M.D. & Saier, M.H., Jr (1993)., A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport., Trends in Biochemical Sciences, 18, 13–20
  58. Reddy, V. S., Shlykov, M. A., Castillo, R., Sun, E. I., & Saier Jr, M. H. (2012)., The major facilitator superfamily (MFS) revisited., The FEBS journal, 279(11), 2022-2035.
  59. Saidijam, M., Benedetti, G., Ren, Q., Xu, Z., Hoyle, C.J., Palmer, S.L., Ward, A., Bettaney, K.E., Szakonyi, G., Meuller, J., Morrison, S., Pos, M.K., Butaye, P., Walravens, K., Langton, K., Herbert, R.B., Skurray, R.A., Paulsen, I.T., O’reilly, J., Rutherford, N.G., Brown, M.H., Bill, R.M. & Henderson, P.J.. (2006)., Microbial drug efflux proteins of the major facilitator superfamily., Current Drug Targets, 7, 793–811.
  60. Schlessinger, A., Khuri, N., Giacomini, K. M., & Sali, A. (2013)., Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters., Current Topics in Medicinal Chemistry, 13, 843-856.